Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Boeing Co (BA) vs BioNano Genomics Inc (BNGO) Price & Performance

Boeing CoTrade
BioNano Genomics IncTrade

Price performance (Past 24H)

Key statistics

Boeing Co vs BioNano Genomics Inc — how do they compare? Boeing Co trades at $217.44 (market cap $171.15B), while BioNano Genomics Inc trades at $1.15 (market cap $13.20M). The key difference: Boeing Co is far larger — about 12965.9× BioNano Genomics Inc's market cap, and Boeing Co pays a 0.03% dividend while BioNano Genomics Inc pays none. Which is the better fit depends on your goals.

BABNGO
Market Cap
$171.15B$13.20M
Volume
7,591,579
Sector
IndustrialsHealth
52-Week High
$252.15$4.92
52-Week Low
$179.12$1.09
Enterprise Value
$197.46B$15.81M
Dividend Yield
0.03%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Boeing Co

Boeing (BA) trades at $215.51, down 3.05% on the day, amid a bearish technical signal. The stock shows mixed fundamentals with a high P/E of 85.18 but improving revenue and net income, reaching $89.46B and $2.24B in 2025, respectively. Recent news highlights potential order wins, including discussions with Riyadh Air for additional 787s, while technical indicators point to support near $209.

Outlook remains cautiously optimistic with a consensus price target of $268.33, implying 24.5% upside, but risks include volatile cash flows, high debt, and ongoing operational challenges. Analyst sentiment is bullish with 66.7% buy ratings, though investors should monitor execution on delivery targets and margin improvements.

BioNano Genomics Inc

Bionano Genomics (BNGO) trades at $1.17, down 2.5% today, but maintains a bullish technical signal with strong moving average support. The company shows improving fundamentals with revenue stabilizing around $29M annually and narrowing losses, though it remains unprofitable with a -109.95% net margin. Recent positive developments include debt retirement and growing adoption of optical genome mapping technology.

BNGO presents a high-risk, high-reward opportunity with analyst consensus leaning bullish (57% buy ratings). The stock trades at attractive valuation multiples (P/S 0.31, P/B 0.36) but faces execution risks in achieving profitability. Key catalysts include continued technology adoption and potential margin improvement, while persistent losses and competitive pressures remain concerns.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Boeing Co

The Boeing Company, together with its subsidiaries, develops, produces, and markets commercial jet aircraft, as well as provides related support services to the commercial airline industry worldwide. The Company also researches, develops, produces, modifies, and supports information, space, and defense systems, including military aircraft, helicopters and space and missile systems.

Read more on BA

About BioNano Genomics Inc

Bionano Genomics Inc is a life sciences instrumentation company in the genome analysis space. It is engaged in the development and marketing of the Saphyr system, a platform for ultra-sensitive and ultra-specific structural variation detection that enables researchers and clinicians to accelerate the search for new diagnostics and therapeutic targets and to streamline the study of changes in chromosomes.

Read more on BNGO